Clinical trial
OPAL - Insulin Glulisine, Diabetes Mellitus
NCT00272012 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00272012 |
|---|---|
| Title | OPAL - Insulin Glulisine, Diabetes Mellitus |
| Official title | Efficacy and Safety of Insulin Glulisine Given as a Single Injection at Breakfast + Insulin Glargine+OAD (Oral Antidiabetic Drug) vs Insulin Glulisine Given as a Single Injection at Main Meal+Insulin Glargine+OAD in Type 2 Diabetic Patients for Which Glycemic Control is Suboptimal Using Insulin… |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus Type 2 |
| Intervention type | Drug |
| Interventions | Insulin glulisine |
| Enrollment | 396 |
| Start date | Jul 1, 2004 |
| Primary completion | Sep 1, 2006 |
| First posted | Jan 4, 2006 |
| Last update posted | Dec 7, 2009 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: